Ibrance Tablet (Palbociclib) 125mg

Ibrance (Palbociclib) 125 mg

0 out of 5

$350.00

IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or fulvestrant in women with disease progression following hormonal therapy.

9223372036854775807 in stock

SKU: Ibrance (Palbociclib) Categories:Pfizer, PRESCRIPTION DRUGS
Compare

Description

Ibrance Tablet (Palbociclib) 125mg

Description

IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or
fulvestrant in women with disease progression following hormonal therapy.

IBRANCE IS THE FIRST FDA-APPROVED MEDICATION in its class.

What is Ibrance?

Ibrance is a targeted therapy that known as a CDK 4/6 inhibitor. It is not traditional chemotherapy. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see Important Safety Information.

A First-Of-Its-Kind Treatment

Which Type of Breast Cancer is It For?

IBRANCE is for women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer—also known as HR+/HER2-.

HR+/HER2-
Hormone receptor-positive includes both estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) subtypes. If your subtype is ER+ and/or PR+, you’re more likely to respond to hormone therapies, like an aromatase inhibitor or fulvestrant, that reduce the effects of hormones.

HR+/HER2-
If your subtype is HER2-, your cancer cells have less HER2 protein expression and, therefore, are less likely to respond to anti-HER2 therapies.

HR+, HER2- is the most common subtype of metastatic breast cancer, representing approximately 60% of all cases.

IBRANCE combination therapy was studied in 2 different clinical trials. Whether you’ve previously received hormonal therapy for your metastatic disease before or not, talk to your healthcare team to learn if IBRANCE is right for you.

How It Works

  • SLOWING THE PROGRESSION OF METASTATIC BREAST CANCER

IBRANCE is a targeted therapy known as a CDK 4/6 inhibitor. It is not traditional chemotherapy. IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious.

Learn How IBRANCE & Hormonal Therapies Work Together
IBRANCE and hormonal therapies bring the power of two therapies together to help delay the progression of a certain type of metastatic breast cancer.

Use the green arrows to navigate the animation below, demonstrating how IBRANCE works to inhibit CDK 4/6 and how hormonal therapies play a role in reducing the effects of hormones in the body.

"<yoastmark

Side Effects of Ibrance

While on therapy, be sure to share any side effects you experience with your healthcare team right away.

  • SERIOUS SIDE EFFECTS

Low white blood cell counts (neutropenia) are very common when taking IBRANCE (palbociclib) and may cause serious infections that can lead to death. Your healthcare team should check your white blood cell counts before and during treatment.

If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

  • COMMON SIDE EFFECTS

In addition to low white blood cell counts (neutropenia), low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare team right away if you feel dizzy or weak; notice that you bleed or bruise more easily, or experience shortness of breath or nosebleeds while on treatment.

Other common side effects include infections, tiredness, nausea, sore mouth, abnormalities in liver blood tests, diarrhea, hair thinning or hair loss, vomiting, rash, and loss of appetite.

Not all of the possible side effects are listed here. For more information, talk to your doctor, nurse, or pharmacist.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.